Combination therapy of a PSEN1-selective γ-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemia

• Charlien Vandersmissen,
• Cristina Prieto,
• Olga Gielen,
• Kris Jacobs,
• David Nittner,
• Johan Maertens,
• Heidi Segers,
• Jan Cools

Affiliations

Charlien Vandersmissen

Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven

Cristina Prieto

Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven

Olga Gielen

Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven

Kris Jacobs

Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven

David Nittner

Center for Cancer biology, VIB, Leuven

Johan Maertens

Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven, Belgium; Department of Hematology, UZ Leuven, Leuven, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven

Heidi Segers

Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium; Department of Pediatric Oncology, UZ Leuven, Leuven

Jan Cools

Center for Human Genetics, KU Leuven, Leuven, Belgium; Center for Cancer biology, VIB, Leuven, Belgium; Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven